April is Testicular Cancer Awareness Month. Thomas L. Jang, MD, MPH, FACS, is chief of urologic oncology at Rutgers Cancer Institute and RWJBarnabas Health shares what young men need to know.
Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company Pfizer to support an innovative new program designed to bolster early cancer detection and prevention efforts. The donation will help build a bridge bringing research discoveries to community health centers and improving access to early detection tests for colorectal, breast, cervical and prostate cancer.
Scientists at the UCLA Health Jonsson Comprehensive Cancer Center and the University of Toronto have revealed how a tiny chemical modification in RNA, known as m6A, plays a critical role in the progression of prostate cancer, including driving some of its most dangerous forms of the disease.
A new large-scale study provides the strongest evidence yet that a shorter, standard-dose course radiation treatment is just as effective as conventional radiotherapy for prostate cancer, without compromising the safety of patients.
A study led by UCLA investigators shows that artificial intelligence (AI) could play a key role in improving treatment outcomes for men with prostate cancer by helping physicians determine who is most likely to benefit from partial gland cryoablation, a minimally invasive procedure that treats localized prostate tumors.
鈥淏eing diagnosed with prostate cancer is not a death knell,鈥� said Montgomery, senior author of a literature and trial review that appeared in JAMA today. Montgomery is the clinical director of Genitourinary Oncology at Fred Hutch Cancer Center and University of Washington Medical Center, and a professor of medicine and urology at the UW School of Medicine.
A genetic mutation in mice affects cells required for sexual reproduction and holds clues about male infertility that could pave the way for new treatments and male contraceptives, a Rutgers University鈥揘ew Brunswick researcher and colleagues have discovered. Writing in Nature Communications, Devanshi Jain, an assistant professor with the Department of Genetics at the School of Arts and Sciences, addresses a fundamental question about how humans and animals develop germ cells that go on to form sperm.
Scientists from UCLA, the University of Toronto and the University of Melbourne have uncovered new genetic clues that explain why some prostate cancers remain slow-growing while others become life-threatening.
The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Researchers have developed a cancer vaccine method that can target virtually any solid tumor, amplifying the visibility of tumor antigens to the immune system, leading to a potent response. Preclinical tests shows that it helps slow or stop the progression of melanoma, triple-negative breast cancer, lung and ovarian cancer
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025. The Dana-Farber led research exemplifies innovative and multidisciplinary expertise in prostate, kidney, and bladder cancers, and includes studies examining novel treatments and predictive biomarkers.
February is National Cancer Prevention Month. Cancer screenings are essential for detecting cancer early鈥攐ften before symptoms appear鈥攚hen treatment is most effective. Learn more about what cancers you can be screened for and when.
A computer model of the cellular environment inside the knee developed by UT Southwestern Medical Center researchers sheds light on why women tend to have worse outcomes after knee injuries than men. Their findings, published in Scientific Reports, could facilitate research into new therapies for knee inflammatory disorders and personalized treatments for patients with these conditions.
Researchers at Vanderbilt and the University of Michigan have shown that a simple at-home urine test for prostate cancer screening is highly accurate. The exciting new results, published in The Journal of Urology, build upon a prior Vanderbilt study of prostate cancer screening that required a digital rectal exam.
Men undergoing radiation therapy for prostate cancer who experience side effects early in treatment may face a higher risk of developing more serious long-term urinary and bowel health issues, according to a new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center.
Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies. However, in addition to being uncomfortable, some of these procedures result in overdiagnosis of low-grade cancers.
The inherited mutated gene WNT9B, which functions normally in embryonic prostate development, increases risk of adult prostate cancer, according to the Vanderbilt University Medical Center study published in JCO Precision Oncology.
The Mount Sinai Hospital has performed New York City鈥檚 first procedure using the HYDROS鈩� Robotic System, a cutting-edge technology designed to treat benign prostatic hyperplasia (BPH), or an enlarged prostate. The minimally invasive procedure offers new hope for patients experiencing the symptoms of BPH, including frequent urination, incomplete bladder emptying, and nighttime urgency. Urologists at the hospital recently performed the health system鈥檚 first three procedures, with all patients responding well to the treatment and being discharged the following day.
A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests 鈥� Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris 鈥� can help doctors make better decisions about how to treat patients with early stage prostate cancer. The review, published in the Annals of Internal Medicine, shows that these tests can provide more detailed information about the cancer, but experts say more data is needed on the cost-effectiveness and clinical utility of these tests, as well as their impact on racial and ethnic groups, especially Black men.
Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising. A group of distinguished Chinese experts has recently developed a comprehensive consensus aimed at addressing critical gaps in prostate cancer management, particularly in areas where high-level evidence is currently lacking. This consensus is designed to guide clinical practice, from screening to treatment and follow-up, offering a standardized approach to improve patient outcomes across the country.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 麻豆传媒 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
